FamGenix vs Progeny Clinical: an honest comparison

This page is a head-to-head comparison of FamGenix and Progeny Clinical. Teams searching "famgenix vs progeny" typically want a plain-English summary of which is the better fit for their cancer genetics service. That is what this page provides. Evagene is briefly introduced at the end as a third option; this article is genuinely about FamGenix and Progeny first. All product claims are drawn from each vendor's public website and documentation as of April 2026.

Short version. Choose FamGenix if you want the most modern cancer-risk-breadth on the market: BOADICEA v6, Tyrer-Cuzick v8, BayesMendel variants, Gail, Claus, and QRISK3 run simultaneously on a single family history, with regional data for US/CA/UK-EU/AU. It launched in 2021, is in 4 of the top 10 US cancer centres, and is cancer-first by design. Choose Progeny Clinical if you want the deepest operational track record — in use since 1996, 800+ genetics institutions, owned by Ambry Genetics — and need mature EHR integration, test ordering, letter generation, and the option of on-premise deployment. Both handle cancer genetics competently; one is the modern specialist and the other is the well-worn generalist.

How FamGenix and Progeny position themselves

FamGenix is a modern cancer-risk-focused platform launched in 2021. Its headline is the breadth and simultaneity of cancer risk models: BOADICEA v6 (the current CanRisk engine for breast and ovarian cancer), Tyrer-Cuzick v8, several BayesMendel family members, Gail (breast), Claus (breast), and QRISK3 (cardiovascular, used in some UK settings alongside cancer screening decisions), all run on one family history without re-entry. It ships regional data for the US, Canada, UK/EU, and Australia, which matters for local incidence rates and guideline alignment. Its customer references include 4 of the top 10 US cancer centres. It is HIPAA and GINA compliant, and offers a free Individual tier alongside institutional pricing.

Progeny Clinical is the professional edition of a clinical pedigree product that has been in use since 1996, owned by Ambry Genetics since 2018. Its installed base is 800+ genetics institutions. It supports both cloud and on-premise deployment, integrated cancer risk modelling, deep EHR integration, test ordering, and letter generation. Cancer genetics is its heritage use case — the product has served US cancer centres for decades — though it is also used for rare disease, reproductive genetics, and general clinical genetics. Progeny is HIPAA-compliant. Pricing is not published; procurement is via quote. User feedback over the years has flagged friction points: moving family members can be awkward, complex features can be unintuitive, and some customers have reported rising prices.

The choice is a classic modern-specialist-vs-incumbent-generalist decision. FamGenix is the 2021-vintage product built explicitly for the cancer genetics use case. Progeny is the 1996-vintage platform that has grown with the field.

Feature comparison

The matrix below compares features each vendor publishes. A tick means the capability is publicly advertised; a dash means it is not publicly listed. Evagene appears as a third column.

Matrix compiled from publicly available product pages and documentation as of April 2026. "—" indicates the capability is not publicly advertised and does not necessarily mean it is absent.

Cancer risk modelling: breadth vs heritage

This is the axis most cancer genetics services care about. FamGenix publishes a specific, current model stack — BOADICEA v6, Tyrer-Cuzick v8, BayesMendel variants, Gail, Claus, QRISK3 — and its central selling point is running them all on one family history so the clinician can compare results and select the model (or combination) appropriate to the case and the guideline. The product is modern enough that its models are on their current major versions and its regional data explicitly tracks incidence differences by country.

Progeny Clinical has integrated cancer risk modelling with a long operational track record. The specific models available in a particular Progeny deployment may depend on the contract tier and the version, and the product does not publish an exhaustive list on the public site. In practice, most Progeny cancer genetics customers have the models they need; customers evaluating Progeny should ask for a current list and confirm which versions are in use. The three-decade operational record is itself a capability, because institutions need pedigree systems whose behaviour they can rely on year over year.

If model-set transparency is a critical procurement criterion, FamGenix gives you more upfront. If long-run operational stability is the criterion, Progeny's heritage is hard to match.

EHR integration, letter generation, and test ordering

Progeny Clinical's public materials emphasise EHR integration, test ordering, and letter generation as part of the cancer genetics workflow. Letter generation in particular — the clinician's summary letter to the referring physician, the family, and the patient — is where a lot of clinical time lives, and having it integrated saves hours per week per clinician. Progeny's heritage makes it likely that any EHR-integration question has been asked and answered before in some form.

FamGenix's integration story is narrower on the public site. The platform is modern and browser-first, but deep institutional EHR integration delivered by the vendor as part of standard deployment is not advertised at the same depth. For a small clinic this is not a problem; for a large hospital wanting a vendor-managed Epic or Cerner integration, Progeny's model is the more recognisable one.

Vendor independence and lab-referral concerns

Progeny Clinical is owned by Ambry Genetics, a clinical diagnostic laboratory. There is no public evidence that Progeny steers ordering inappropriately; the product long predated the Ambry acquisition. But institutions with strict conflict-of-interest policies — or that simply prefer not to have their pedigree tool under the ownership of a testing vendor — sometimes prefer an independent software vendor. This is a preference, not a scandal, and it affects only a subset of procurement committees.

FamGenix is an independent vendor and does not bundle test ordering, which for some institutions makes vendor-neutrality easier to demonstrate. For others this is not a factor.

Pricing and free access

Both products offer a form of free access, but they are meaningfully different. FamGenix's free Individual tier is aimed at individual users exploring their own family history — useful for patient self-use, and useful for clinicians who want to see the product's UX without a contract. Progeny Cloud is a free, stripped-down cloud edition of Progeny Clinical, targeted at small clinics and new services as a genuine clinical tool (with advanced features gated behind paid Progeny Clinical).

Neither institutional tier is publicly priced. Budget planning should include a vendor quote from each.

When to choose FamGenix

• You want modern cancer-risk breadth (BOADICEA v6, Tyrer-Cuzick v8, BayesMendel variants, Gail, Claus, QRISK3) run simultaneously on a single family history.
• You value regional data for US, Canada, UK/EU, or Australia and NCCN-aligned workflow.
• You want a product that launched in 2021 and is actively developed on a modern cadence.
• You prefer a vendor that is independent of clinical diagnostic laboratories.
• Your institution does not require deep vendor-managed EHR integration, test ordering, and letter generation at the depth a long-established vendor would ship.

When to choose Progeny Clinical

• You value a 30-year operational track record and 800+ genetics institution installed base.
• Your institution requires mature, vendor-managed EHR integration, test ordering, and letter generation.
• You need on-premise deployment, or the option of it, alongside cloud.
• Your team is comfortable with the fact that Progeny is owned by Ambry Genetics (a clinical diagnostic laboratory).
• You want a clear upgrade path from the free Progeny Cloud to paid Progeny Clinical as your clinic grows.

A third option to consider: Evagene

FamGenix and Progeny Clinical are both credible cancer genetics platforms. For services whose requirements include modern AI integration, a public REST API, and an MCP server for AI agents — capabilities neither FamGenix nor Progeny publicly prioritise — Evagene is worth evaluating alongside them.

Evagene is a browser-based clinical pedigree management platform with gesture drawing, a 200+ disease catalogue coded to ICD-10 and OMIM, integrated BayesMendel cancer risk models (BRCAPRO, MMRpro, PancPRO), Mendelian inheritance analysis for AD/AR/XR patterns, karyogram viewing, and consanguinity detection via Wright's coefficient. Evagene's cancer risk coverage is narrower than FamGenix's — if your service depends on BOADICEA v6 or Tyrer-Cuzick v8 specifically, FamGenix is a better fit today — but Evagene covers the core BayesMendel set cleanly and adds a batch risk screening feature that sweeps across all 200+ catalogued diseases for a given proband.

Evagene's AI layer is bring-your-own-key: the service provides its own Anthropic Claude or OpenAI GPT credentials, encrypted at rest with Fernet. Analysis Templates codify house style of report writing with variable injection. The MCP server exposes 11 pedigree tools to Claude Desktop, Claude Code, and any other MCP-compatible AI agent, so clinicians can ask their AI assistant to read, modify, or analyse a pedigree directly. The integration surface comprises a scoped, rate-limited REST API with keys in the format evg_ followed by 43 characters (SHA-256 hashed at rest), HMAC-SHA256-signed webhooks, and an embeddable pedigree viewer (iframe / SVG / JavaScript). Imports cover GEDCOM 5.5.1, JSON, 23andMe, XEG, and pedigree image OCR.

Evagene is in Alpha and free via waiting list at evagene.com. It does not replace FamGenix's cancer-risk-breadth or Progeny's EHR-integration depth for institutions that need those today. It offers a credible modern alternative for services whose priorities are AI-assisted interpretation and programmable integration.

Frequently asked questions

Related reading

• FamGenix vs Evagene
• Progeny vs Evagene
• FamGenix vs Phenotips
• Phenotips vs Progeny
• Pedigree drawing software: a practical guide
• All Evagene comparisons